Pitcairn Co. reduced its holdings in shares of HCA Healthcare, Inc. (NYSE:HCA – Free Report) by 25.2% in the third quarter, Holdings Channel.com reports. The fund owned 3,528 shares of the company’s stock after selling 1,190 shares during the quarter. Pitcairn Co.’s holdings in HCA Healthcare were worth $1,434,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also bought and sold shares of HCA. Bangor Savings Bank raised its position in HCA Healthcare by 112.5% during the 2nd quarter. Bangor Savings Bank now owns 85 shares of the company’s stock valued at $27,000 after purchasing an additional 45 shares in the last quarter. MFA Wealth Advisors LLC bought a new stake in HCA Healthcare during the 2nd quarter valued at $27,000. Unique Wealth Strategies LLC bought a new stake in HCA Healthcare during the 2nd quarter valued at $28,000. GPS Wealth Strategies Group LLC raised its position in HCA Healthcare by 284.0% during the 2nd quarter. GPS Wealth Strategies Group LLC now owns 96 shares of the company’s stock valued at $31,000 after purchasing an additional 71 shares in the last quarter. Finally, Benjamin F. Edwards & Company Inc. purchased a new position in shares of HCA Healthcare in the 2nd quarter valued at $33,000. 62.73% of the stock is owned by institutional investors.
HCA Healthcare Stock Performance
NYSE HCA opened at $324.93 on Friday. The stock has a market capitalization of $82.30 billion, a price-to-earnings ratio of 14.59, a PEG ratio of 1.28 and a beta of 1.68. HCA Healthcare, Inc. has a twelve month low of $245.84 and a twelve month high of $417.14. The company has a current ratio of 1.12, a quick ratio of 1.00 and a debt-to-equity ratio of 48.71. The stock has a 50-day moving average of $379.40 and a 200 day moving average of $358.35.
HCA Healthcare Announces Dividend
Wall Street Analysts Forecast Growth
A number of research analysts have recently issued reports on HCA shares. Truist Financial lifted their price target on HCA Healthcare from $390.00 to $430.00 and gave the company a “buy” rating in a report on Monday, August 19th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $392.00 price target on shares of HCA Healthcare in a report on Tuesday, October 1st. Raymond James downgraded HCA Healthcare from an “outperform” rating to a “market perform” rating in a report on Friday. Wells Fargo & Company boosted their target price on HCA Healthcare from $395.00 to $400.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 6th. Finally, Oppenheimer boosted their target price on HCA Healthcare from $390.00 to $400.00 and gave the stock an “outperform” rating in a research note on Monday, October 28th. Six research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $385.00.
Check Out Our Latest Analysis on HCA Healthcare
Insider Buying and Selling
In other HCA Healthcare news, SVP Phillip G. Billington sold 3,897 shares of the business’s stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $350.00, for a total transaction of $1,363,950.00. Following the completion of the sale, the senior vice president now directly owns 52,702 shares in the company, valued at approximately $18,445,700. The trade was a 6.89 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Erol R. Akdamar sold 2,900 shares of the business’s stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $353.00, for a total value of $1,023,700.00. Following the sale, the insider now owns 6,843 shares of the company’s stock, valued at approximately $2,415,579. This trade represents a 29.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 15,155 shares of company stock valued at $5,608,990. 1.60% of the stock is owned by company insiders.
HCA Healthcare Company Profile
HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.
Recommended Stories
- Five stocks we like better than HCA Healthcare
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
- Profitably Trade Stocks at 52-Week Highs
- MarketBeat Week in Review – 11/18 – 11/22
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 2 Finance Stocks With Competitive Advantages You Can’t Ignore
Want to see what other hedge funds are holding HCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCA Healthcare, Inc. (NYSE:HCA – Free Report).
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.